Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
05/22/2024 | Press release | Distributed by Public on 05/21/2024 18:36
Please select the service you want to use:
Smartlinks | Savor Ltd. | Company News | Top Company News | Corporate and Financial Calendar | Manufacturing | Food Industry | Beverages | Alcoholic Beverages | Restaurants, Bars and Food Services | Travel, Leisure and Recreation Industry | Securities Issuers | Beer Manufacturers and Distributors | New Zealand Exchange (NZX)
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact